Chemical Component Summary

NameClopidogrel
Synonymsmethyl (2S)-(2-chlorophenyl)(6,7-dihydrothieno[3,2-c]pyridin-5(4H)-yl)ethanoate
Identifiersmethyl (2S)-2-(2-chlorophenyl)-2-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)ethanoate
FormulaC16 H16 Cl N O2 S
Molecular Weight321.82
TypeNON-POLYMER
Isomeric SMILESCOC(=O)[C@H](c1ccccc1Cl)N2CCc3c(ccs3)C2
InChIInChI=1S/C16H16ClNO2S/c1-20-16(19)15(12-4-2-3-5-13(12)17)18-8-6-14-11(10-18)7-9-21-14/h2-5,7,9,15H,6,8,10H2,1H3/t15-/m0/s1
InChIKeyGKTWGGQPFAXNFI-HNNXBMFYSA-N

Chemical Details

Formal Charge0
Atom Count37
Chiral Atom Count1
Bond Count39
Aromatic Bond Count11

Drug Info: DrugBank

DrugBank IDDB00758 
NameClopidogrel
Groupsapproved
DescriptionClopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke.[A180508,L7213] Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213] It has been shown to be superior to [aspirin] in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.[A180547] Clopidogrel was granted FDA approval on 17 November 1997.[L7213]
Synonyms
  • Clopidogrel
  • Clopidogrelum
  • Clopidogrel besilate
  • Clopidogrel hydrochloride
  • (+)-Clopidogrel
Brand Names
  • Priva-clopidogrel
  • Clopidogrel Zentiva
  • Mint-clopidogrel
  • Nra-clopidogrel
  • Clopidogrel
IndicationClopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,[L7213]
Categories
  • Antiplatelet agents
  • Blood and Blood Forming Organs
  • Cytochrome P-450 CYP1A2 Substrates
  • Cytochrome P-450 CYP2B6 Inhibitors
  • Cytochrome P-450 CYP2B6 Inhibitors (moderate)
ATC-CodeB01AC04
CAS number113665-84-2

Drug Targets

NameTarget SequencePharmacological ActionActions
P2Y purinoceptor 12MQAVDNLTSAPGNTSLCTRDYKITQVLFPLLYTVLFFVGLITNGLAMRIF...unknownantagonist
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
Cytochrome P450 2B6MELSVLLFLALLTGLLLLLVQRHPNTHDRLPPGPRPLPLLGNLLQMDRRG...unknownsubstrate,inhibitor
Cytochrome P450 3A5MDLIPNLAVETWLLLAVSLVLLYLYGTRTHGLFKRLGIPGPTPLPLLGNV...unknownsubstrate
Cytochrome P450 2C19MDPFVVLVLCLSCLLLLSIWRQSSGRGKLPPGPTPLPVIGNILQIDIKDV...unknownsubstrate
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
CCDC/CSDFUQMOU
PubChem60606
ChEBICHEBI:37941
ChEMBLCHEMBL1771
PharosCHEMBL1771